ClinicaliQ Trial Snapshot
- A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine — Recruiting • Phase III • NCT04965675.
- Eptinezumab reduced migraine days more than placebo in teenagers aged 12-17 with chronic migraine.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine. Conditions: Chronic Migraine in Children Interventions: Eptinezumab, Placebo Lead Sponsor: H. Lundbeck A/S Planned Enrollment: 285 participants